On this page
- TL;DR
- Psoriatic arthritis VA rating criteria (DC 5002)
- Rating psoriatic arthritis by joint residuals (DC 5003)
- Psoriatic arthritis and psoriasis ratings
- The psoriatic arthritis C&P exam and evidence
- How to prove psoriatic arthritis is service connected
- Why VA denies psoriatic arthritis claims
- Questions veterans ask about psoriatic arthritis
- Bottom Line
- Related Conditions and Tools
- Sources and limits
Psoriatic arthritis is expressly included in Diagnostic Code 5002, the active-process code for multi-joint arthritis involving two or more joints. Current 38 CFR § 4.71a creates two possible rating paths: rate the active systemic disease under DC 5002, or rate chronic residuals under DC 5003 and the appropriate joint codes. VA does not add the two paths together. It assigns the higher evaluation.
That distinction matters because an inflammatory flare history and permanent joint damage prove different things. A one-day range-of-motion exam may document residual damage but miss the frequency and severity of the active disease. A useful record has to show both.
This page covers the DC 5002 rating criteria, rating joint residuals instead, how psoriatic arthritis and psoriasis are rated side by side, the evidence for the C&P exam, how to prove service connection, and why VA denies these claims.
TL;DR
- DC 5002 covers active psoriatic arthritis affecting two or more joints.
- The active-process levels are 20, 40, 60, and 100 percent.
- Chronic residuals are rated under DC 5003 and, when applicable, the limitation-of-motion or ankylosis code for each affected joint.
- Active-process and residual evaluations do not stack. VA must compare them and assign the higher evaluation.
- Psoriasis of the skin is a separate diagnosis under DC 7816, and the note to DC 7816 says to rate psoriatic arthritis separately. Separate compensation still requires distinct manifestations rather than double payment for the same impairment.
- Service connection requires evidence for the individual veteran. Combat stress, toxic exposure, PTSD, or depression should not be presented as automatic causes of psoriatic arthritis.
- Across 520 decided Board rulings on psoriatic arthritis from 2021 to 2026, 28.5% were granted, 14.4% denied and 57.1% remanded. The Board section below breaks those rulings down.
Psoriatic arthritis VA rating criteria (DC 5002)
DC 5002 provides four active-process levels.
20 percent
One or two exacerbations per year in a well-established diagnosis.
40 percent
Symptom combinations that produce definite impairment of health and are objectively supported by examination findings, or incapacitating exacerbations occurring three or more times per year.
60 percent
Less than the 100-percent criteria, but with weight loss and anemia producing severe impairment of health, or severely incapacitating exacerbations occurring four or more times per year, or fewer exacerbations that continue over prolonged periods.
100 percent
Constitutional manifestations associated with active joint involvement that are totally incapacitating.
These levels focus on the disease over time. Treatment notes should identify how many exacerbations occurred, how long they lasted, whether they were incapacitating, and whether the disease caused objectively documented impairment of overall health. A statement that the veteran “has flares” does not establish the frequency or severity required by the schedule.
DC 5002's Note (1) names psoriatic arthritis, along with rheumatoid arthritis and spondyloarthropathies, as conditions rated under the code. That wording took effect February 7, 2021. Before then, DC 5002 was titled for rheumatoid arthritis, and a decision from that period may list psoriatic arthritis under DC 5009, then titled "Arthritis, other types (specify)." DC 5009 is now "Other specified forms of arthropathy," and its note sends the acute phase to DC 5002 and chronic residuals to DC 5003, so the criteria are the same.
Rating psoriatic arthritis by joint residuals (DC 5003)
DC 5002 Note (2) directs VA to rate chronic residuals under DC 5003. Note (3) then says the active-process rating cannot be combined with ratings for limitation of motion, ankylosis, or DC 5003. VA must use the higher evaluation.
For residuals, identify every joint that has chronic limitation or ankylosis and document it under that joint's code. When limitation of motion is present but not compensable under the joint-specific code, DC 5003 may provide a minimum rating when its objective requirements are met. The exact result depends on the affected joints, measured motion, painful motion, ankylosis, and the bilateral-factor rules when paired extremities are involved.
The correct comparison has three steps.
- Calculate the active-process evaluation under DC 5002.
- Calculate the chronic-residual evaluation under DC 5003 and the appropriate joint codes.
- Assign the higher route without combining both.
Psoriatic arthritis and psoriasis ratings
Psoriasis is a skin disease evaluated under DC 7816. Psoriatic arthritis is the inflammatory joint disease described in DC 5002. A veteran can have both diagnoses, but the record must identify distinct manifestations. The note to DC 7816 in 38 CFR § 4.118 says to rate complications such as psoriatic arthritis separately under the appropriate diagnostic code.
Skin coverage and treatment route support the psoriasis analysis. Joint exacerbations, systemic impairment, limited motion, and ankylosis support the arthritis analysis. The anti-pyramiding rule in 38 CFR § 4.14 prevents duplicate compensation for the same functional loss, but it does not erase genuinely separate skin and joint impairment.
The psoriatic arthritis C&P exam and evidence
Useful records for the active process include the following.
- the rheumatology diagnosis and the joints involved;
- treatment notes distinguishing active inflammation from chronic residual damage;
- a dated flare or exacerbation log;
- urgent-care, emergency, or physician records from severe exacerbations;
- laboratory and examination findings that objectively support impairment of health;
- weight and anemia records when those findings are part of the claimed level;
- medication history, including dose changes and treatment failures; and
- lay statements describing duration and functional impact without trying to make a medical diagnosis.
For residuals, preserve joint-specific range-of-motion testing, painful-motion findings, imaging, ankylosis findings, and functional loss during repeated use or flares. The active and residual records should be developed together even though the resulting evaluations do not stack.
How to prove psoriatic arthritis is service connected
Direct service connection under 38 CFR § 3.303 requires a current disability, an in-service disease, injury, event, or onset, and a link between the two. Service treatment records showing inflammatory joint findings, psoriasis with evolving joint symptoms, dactylitis, enthesitis, nail changes, or a rheumatology assessment can be important, but a clinician must interpret their relationship to the current diagnosis.
A secondary claim under 38 CFR § 3.310 needs competent evidence that a service-connected disability or its treatment caused or aggravated the psoriatic arthritis. An association or shared diagnosis is not enough by itself. The most direct secondary theory is service-connected psoriasis: a 2024 review in the BMJ reports that psoriatic arthritis affects around 30 percent of people with psoriasis, and the note to DC 7816 treats it as a complication of psoriasis. The opinion should still explain the link in your case, and for aggravation it should say whether the arthritis is aggravated by the service-connected condition, meaning it would be less severe but for that condition.
Do not treat combat stress, burn-pit exposure, PTSD, or depression as established medical causes simply because they appear in the veteran's history. A case-specific medical opinion must explain the proposed mechanism, timing, and competing causes.
Arthritis is on the chronic disease list in 38 CFR § 3.309(a), which allows a presumption when the disease shows up to a degree of 10 percent or more within one year after separation (§ 3.307(a)(3)). This page does not assume that listing covers every psoriatic arthritis claim; whether it applies should be reviewed against the precise diagnosis and current authority in the individual case.
Why VA denies psoriatic arthritis claims
Psoriatic arthritis claims do a little better at the Board than the average claim, but more than half are sent back for more development first. Across 520 decided Board rulings on psoriatic arthritis from 2021 to 2026, 28.5% were granted, 14.4% denied and 57.1% remanded. That grant rate is 3.8 points above the Board-wide 24.7 percent, and the remand share is well above the Board-wide 45.2 percent.
Too few psoriatic arthritis service connection claims were denied outright for a reliable breakdown of denial reasons. In the ones the Board did deny, the link to service was missing in each, and in many the record also showed no in-service event or onset. These patterns repeat.
No medical link to service. The records show a later diagnosis, but no opinion explains why it traces to joint or skin findings in service.
Nothing in service. Service records show no joint complaints, psoriasis, or treatment, and the first diagnosis comes years after discharge with no account of the gap.
An automatic theory. A stress, exposure, or mental-health theory is presented as an automatic nexus, without a case-specific medical explanation.
A secondary opinion that skips aggravation. An opinion that says only "not caused by" and never addresses whether the service-connected condition made the arthritis worse is inadequate (El-Amin v. Shinseki, 26 Vet. App. 136 (2013)).
Rating errors repeat too.
- Rating only joint motion and never evaluating the active disease under DC 5002.
- Counting active-process and residual ratings together.
- Describing flares without dates, duration, frequency, or objective support.
- Treating psoriasis skin symptoms as proof of the arthritis percentage.
- Assigning every painful joint to psoriatic arthritis without medical attribution.
When the Board sends a psoriatic arthritis claim back instead of deciding it, the most common reason is an inadequate VA exam or opinion, followed by records VA still had to get. The Board section below shows the remand reasons, results by what the appeal asked for, and how claims argued as direct, secondary and presumptive have fared.
Questions veterans ask about psoriatic arthritis
What is the highest VA rating for psoriatic arthritis?
100 percent under DC 5002, for constitutional manifestations associated with active joint involvement that are totally incapacitating. If rating the residuals of each affected joint gives a higher result, VA uses that instead, but it never pays both.
Can psoriatic arthritis be secondary to psoriasis?
Yes. If your psoriasis is service connected, psoriatic arthritis can be service connected as secondary to it with a medical opinion that links the two in your case. The note to DC 7816 tells VA to rate psoriatic arthritis separately from the skin disease.
Can I get separate VA ratings for psoriasis and psoriatic arthritis?
Yes, when each causes distinct impairment. The note to DC 7816 says to rate complications such as psoriatic arthritis separately, so the skin is rated under DC 7816 and the joints under DC 5002 or the residual codes. Under 38 CFR § 4.14, VA cannot count the same symptom under both.
What diagnostic code is used for psoriatic arthritis?
DC 5002, whose Note (1) has named psoriatic arthritis since February 7, 2021. Older decisions may show DC 5009, the code for other forms of arthritis, which also rates the active phase under DC 5002 and chronic residuals under DC 5003.
Is psoriatic arthritis rated the same as rheumatoid arthritis?
Yes. DC 5002 rates both as multi-joint arthritis affecting two or more joints, with the same 20, 40, 60 and 100 percent levels and the same choice between the active process and joint residuals. The rheumatoid arthritis page covers that condition's claims.
Bottom Line
Psoriatic arthritis has a two-path rating structure. DC 5002 rates the active multi-joint disease at 20, 40, 60, or 100 percent. Chronic residuals are rated through DC 5003 and the affected-joint codes. VA must calculate both paths and assign the higher, not stack them. The strongest record separates active exacerbations, permanent joint damage, and psoriasis skin manifestations, then supports service connection with evidence specific to the veteran.
Related Conditions and Tools
Compare psoriasis, arthritis, and rheumatoid arthritis. Review DC 5002 and DC 5003, and organize functional evidence with the Statement Builder.
Sources and limits
Legal sources: 38 CFR § 4.71a, § 4.14, § 3.303, and § 3.310, along with § 4.118 (the DC 7816 note), §§ 3.307 and 3.309(a), and § 4.26, checked October 6, 2026 against the eCFR text current on October 1, 2026. The history of DC 5002 and DC 5009 comes from VA's musculoskeletal rule (85 FR 76453, November 30, 2020, effective February 7, 2021) and its 2017 proposed rule (82 FR 35719). The aggravation standard is from El-Amin v. Shinseki, 26 Vet. App. 136 (2013).
Medical source, read as a PubMed abstract: Kharouf and Gladman, "Advances in the management of psoriatic arthritis in adults," BMJ (2024).
Board figures come from Claim Raven's read of 510,968 Board decisions from 2021 to 2026, which contain 1,376,193 rulings. Of 577 Board rulings on psoriatic arthritis, 520 were decided; dismissed, withdrawn and moot rulings are excluded from the shares, and the Board section below is computed from the same data. These are Board patterns, not predictions of an individual outcome.
